HDL Therapeutics, Inc. is pioneering a novel approach to the treatment of atherosclerosis, specifically targeting vulnerable plaques that pose significant risks for serious cardiac events. The company’s flagship technology, the PDS-2™ System, is the only FDA-approved therapy designed to leverage high-density lipoprotein (HDL), commonly referred to as "good cholesterol," to actively regress arterial plaques in patients with Homozygous Familial Hypercholesterolemia (HoFH). This innovative system utilizes the patient's own plasma to generate natural pre-β HDL, the specific form of HDL capable of shrinking plaques, thereby reducing the cardiovascular risks associated with atherosclerosis.

The focus of HDL Therapeutics is on addressing the needs of patients with severe forms of atherosclerosis, particularly those with HoFH, a rare genetic disorder that leads to dangerously high levels of low-density lipoprotein cholesterol (LDL-C) and premature heart disease. By increasing the body’s natural HDL levels, the company aims not only to stabilize but also to regress plaques, offering a transformative therapeutic option that can be used alongside existing lipid-lowering treatments. This unique HDL-targeted platform positions HDL Therapeutics at the forefront of cardiovascular disease management, with the potential to significantly improve patient outcomes in a population with high unmet medical needs.

United States

HDL Therapeutics is a clinical-stage company that researches, develops and commercializes therapeutics for the treatment of heart-related problems.

HDL Therapeutics, Inc.

Company Details